A careful reassessment of anthracycline use in curable breast cancer

Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/aad7894979b94db08a790483d6338a18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aad7894979b94db08a790483d6338a18
record_format	dspace
spelling	oai:doaj.org-article:aad7894979b94db08a790483d6338a182021-12-02T19:16:12ZA careful reassessment of anthracycline use in curable breast cancer10.1038/s41523-021-00342-52374-4677https://doaj.org/article/aad7894979b94db08a790483d6338a182021-10-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00342-5https://doaj.org/toc/2374-4677Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of agents, leading some to question their widespread use, especially when newer agents with improved therapeutic indices have become available. Critically assessing when to incorporate an anthracycline is made more relevant in an era where molecular classification is enabling not only the development of biologically targeted therapeutics but also is improving the ability to better select those who would benefit from cytotoxic agents. This comprehensive analysis will present the problem of overtreatment in early-stage breast cancer, review evidence supporting the use of anthracyclines in the pre-taxane era, analyze comparative trials evaluating taxanes with or without anthracyclines in biologically unselected and selected patient populations, and explore published work aimed at defining anthracycline-sensitive tumor types.Sara Alsterlind HurvitzNicholas P. McAndrewAditya BardiaMichael F. PressMark PegramJohn P. CrownPeter A. FaschingBent EjlertsenEric H. YangJohn A. GlaspyDennis J. SlamonNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-25 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sara Alsterlind Hurvitz Nicholas P. McAndrew Aditya Bardia Michael F. Press Mark Pegram John P. Crown Peter A. Fasching Bent Ejlertsen Eric H. Yang John A. Glaspy Dennis J. Slamon A careful reassessment of anthracycline use in curable breast cancer
description	Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of agents, leading some to question their widespread use, especially when newer agents with improved therapeutic indices have become available. Critically assessing when to incorporate an anthracycline is made more relevant in an era where molecular classification is enabling not only the development of biologically targeted therapeutics but also is improving the ability to better select those who would benefit from cytotoxic agents. This comprehensive analysis will present the problem of overtreatment in early-stage breast cancer, review evidence supporting the use of anthracyclines in the pre-taxane era, analyze comparative trials evaluating taxanes with or without anthracyclines in biologically unselected and selected patient populations, and explore published work aimed at defining anthracycline-sensitive tumor types.
format	article
author	Sara Alsterlind Hurvitz Nicholas P. McAndrew Aditya Bardia Michael F. Press Mark Pegram John P. Crown Peter A. Fasching Bent Ejlertsen Eric H. Yang John A. Glaspy Dennis J. Slamon
author_facet	Sara Alsterlind Hurvitz Nicholas P. McAndrew Aditya Bardia Michael F. Press Mark Pegram John P. Crown Peter A. Fasching Bent Ejlertsen Eric H. Yang John A. Glaspy Dennis J. Slamon
author_sort	Sara Alsterlind Hurvitz
title	A careful reassessment of anthracycline use in curable breast cancer
title_short	A careful reassessment of anthracycline use in curable breast cancer
title_full	A careful reassessment of anthracycline use in curable breast cancer
title_fullStr	A careful reassessment of anthracycline use in curable breast cancer
title_full_unstemmed	A careful reassessment of anthracycline use in curable breast cancer
title_sort	careful reassessment of anthracycline use in curable breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/aad7894979b94db08a790483d6338a18
work_keys_str_mv	AT saraalsterlindhurvitz acarefulreassessmentofanthracyclineuseincurablebreastcancer AT nicholaspmcandrew acarefulreassessmentofanthracyclineuseincurablebreastcancer AT adityabardia acarefulreassessmentofanthracyclineuseincurablebreastcancer AT michaelfpress acarefulreassessmentofanthracyclineuseincurablebreastcancer AT markpegram acarefulreassessmentofanthracyclineuseincurablebreastcancer AT johnpcrown acarefulreassessmentofanthracyclineuseincurablebreastcancer AT peterafasching acarefulreassessmentofanthracyclineuseincurablebreastcancer AT bentejlertsen acarefulreassessmentofanthracyclineuseincurablebreastcancer AT erichyang acarefulreassessmentofanthracyclineuseincurablebreastcancer AT johnaglaspy acarefulreassessmentofanthracyclineuseincurablebreastcancer AT dennisjslamon acarefulreassessmentofanthracyclineuseincurablebreastcancer AT saraalsterlindhurvitz carefulreassessmentofanthracyclineuseincurablebreastcancer AT nicholaspmcandrew carefulreassessmentofanthracyclineuseincurablebreastcancer AT adityabardia carefulreassessmentofanthracyclineuseincurablebreastcancer AT michaelfpress carefulreassessmentofanthracyclineuseincurablebreastcancer AT markpegram carefulreassessmentofanthracyclineuseincurablebreastcancer AT johnpcrown carefulreassessmentofanthracyclineuseincurablebreastcancer AT peterafasching carefulreassessmentofanthracyclineuseincurablebreastcancer AT bentejlertsen carefulreassessmentofanthracyclineuseincurablebreastcancer AT erichyang carefulreassessmentofanthracyclineuseincurablebreastcancer AT johnaglaspy carefulreassessmentofanthracyclineuseincurablebreastcancer AT dennisjslamon carefulreassessmentofanthracyclineuseincurablebreastcancer
_version_	1718376990875058176

A careful reassessment of anthracycline use in curable breast cancer

Ejemplares similares